Saudi Arabia’s Capital Market Authority (CMA) said on 31 August 2026 that Lamha Tanbu had completed the commencement-of-business requirements for a fintech experiment permit involving the use of artificial intelligence in advisory. The permit followed a CMA Board decision dated 14 May 2025. The August announcement is therefore not the date a new permit was granted; it is a separate regulatory update that the start-up requirements under an earlier experimental permit had been met. That operational milestone is the event covered here.

The CMA announcement identifies the experiment as AI use in advisory but does not explain how the product works, whether it is available to customers, which assets or customer groups it covers, or how the algorithm performs. It gives no public numerical result for customers, assets under management, investment returns or model accuracy. The article consequently does not describe a product launch, broad deployment or the scale of an investment-advice service.

AI in financial advice could support tailored recommendations and operations, while also raising questions about data quality, model explainability, conflicts of interest, suitability assessment and human oversight. The CMA release does not report the specific control design or test results for this experiment. Those are general issues for evaluating such a test, not verified findings about this company. Meeting commencement requirements does not mean the regulator has endorsed every recommendation the system may produce.

The economic significance is that a controlled experiment involving AI advice passed the operational start requirements within the capital-market regulatory framework. A permit record alone does not prove that the technology is safe, accurate or commercially successful. Further primary disclosures would be needed on the test’s scope, customer access, performance or complaint data, and any later authorisations. As of 31 August, the supported finding is limited to Lamha Tanbu completing the commencement requirements under its experimental permit.

This limited source record keeps the distinction between regulatory permission and a financial product offered to consumers. Later trial reporting could provide more meaningful evidence on safety and advice quality; the present announcement does not substitute for those results.